QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
Log in
CVE:ATE

Antibe Therapeutics Inc. (ATE.V) Stock Forecast, Price & News

C$0.40
+0.02 (+5.19 %)
(As of 11/11/2020)
Add
Compare
Today's Range
C$0.39
Now: C$0.41
C$0.41
50-Day Range
C$0.41
MA: C$0.41
C$0.41
52-Week Range
C$0.31
Now: C$0.41
C$0.89
Volume1.25 million shs
Average Volume1.35 million shs
Market CapitalizationC$156.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

MarketRank

Overall MarketRank

1.27 out of 5 stars

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-5705103
Employees47
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$8.45 million
Cash FlowC$0.09 per share
Book ValueC$0.08 per share

Profitability

Miscellaneous

Market CapC$156.11 million
Next Earnings Date2/22/2021 (Estimated)
OptionableNot Optionable
C$0.40
+0.02 (+5.19 %)
(As of 11/11/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive ATE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antibe Therapeutics Inc. (ATE.V) (CVE:ATE) Frequently Asked Questions

How has Antibe Therapeutics Inc. (ATE.V)'s stock been impacted by Coronavirus?

Antibe Therapeutics Inc. (ATE.V)'s stock was trading at C$0.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATE shares have decreased by 27.7% and is now trading at C$0.41.
View which stocks have been most impacted by COVID-19
.

Is Antibe Therapeutics Inc. (ATE.V) a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics Inc. (ATE.V) in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Antibe Therapeutics Inc. (ATE.V) stock.
View analyst ratings for Antibe Therapeutics Inc. (ATE.V)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Antibe Therapeutics Inc. (ATE.V)?

Wall Street analysts have given Antibe Therapeutics Inc. (ATE.V) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antibe Therapeutics Inc. (ATE.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Antibe Therapeutics Inc. (ATE.V)'s next earnings date?

Antibe Therapeutics Inc. (ATE.V) is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Antibe Therapeutics Inc. (ATE.V)
.

Is Antibe Therapeutics Inc. (ATE.V) a good dividend stock?

Antibe Therapeutics Inc. (ATE.V) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.
View Antibe Therapeutics Inc. (ATE.V)'s dividend history.

What price target have analysts set for ATE?

3 analysts have issued 12-month price targets for Antibe Therapeutics Inc. (ATE.V)'s shares. Their forecasts range from C$1.00 to C$1.50. On average, they expect Antibe Therapeutics Inc. (ATE.V)'s share price to reach C$1.25 in the next year. This suggests a possible upside of 208.6% from the stock's current price.
View analysts' price targets for Antibe Therapeutics Inc. (ATE.V)
or view Wall Street analyst' top-rated stocks.

Who are some of Antibe Therapeutics Inc. (ATE.V)'s key competitors?

What other stocks do shareholders of Antibe Therapeutics Inc. (ATE.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antibe Therapeutics Inc. (ATE.V) investors own include Resverlogix Corp. (RVX.TO) (RVX), Terra Tech (TRTC), Green Bancorp (GNBC), Tesla (TSLA), 1302 (CFE), Maxar Technologies Inc. (MAXR.TO) (MAXR), Nemaska Lithium Inc. (NMX.TO) (NMX), Royal Bank of Canada (RY.TO) (RY), Scorpio Gold Co. (SGN.V) (SGN) and Cronos Group (CRON).

Who are Antibe Therapeutics Inc. (ATE.V)'s key executives?

Antibe Therapeutics Inc. (ATE.V)'s management team includes the following people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 62, Pay $311.22k)
  • Dr. John Lawrence Wallace M.B.A., M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director (Age 63, Pay $311.22k)
  • Mr. Alain Wilson M.B.A., MBA, Chief Financial Officer
  • Dr. David James Vaughan, Chief Devel. Officer (Age 70, Pay $229.82k)
  • Mr. Scott Curtis C.F.A., M.Eng, CFA, Exec. VP
  • Ms. Christina Cameron B.B.A., VP of Investor Relations
  • Mr. Philip Stern, VP of Communications
  • Dr. Rami Batal M.B.A., Ph.D., Chief Commercial Officer
  • Ms. Ella Korets Smith M.B.A., M.Sc., Head of Regional Bus. Devel.
  • Dr. Joseph Stauffer, Chief Medical Officer (Age 54)

What is Antibe Therapeutics Inc. (ATE.V)'s stock symbol?

Antibe Therapeutics Inc. (ATE.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

How do I buy shares of Antibe Therapeutics Inc. (ATE.V)?

Shares of ATE and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is Antibe Therapeutics Inc. (ATE.V)'s stock price today?

One share of ATE stock can currently be purchased for approximately C$0.41.

How big of a company is Antibe Therapeutics Inc. (ATE.V)?

Antibe Therapeutics Inc. (ATE.V) has a market capitalization of C$156.11 million and generates C$8.45 million in revenue each year. Antibe Therapeutics Inc. (ATE.V) employs 47 workers across the globe.

What is Antibe Therapeutics Inc. (ATE.V)'s official website?

The official website for Antibe Therapeutics Inc. (ATE.V) is www.antibethera.com.

How can I contact Antibe Therapeutics Inc. (ATE.V)?

Antibe Therapeutics Inc. (ATE.V)'s mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The company can be reached via phone at +1-905-5705103.

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.